432 related articles for article (PubMed ID: 17682796)
21. [Osteoporosis treatment in Portugal: trends and geographical variation].
Rocha O; Lunet N; Costa L; Barros H
Acta Med Port; 2006; 19(5):373-80. PubMed ID: 17376323
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
23. [Osteoporosis: from cost-effect characteristics to clinical efficacy and safety of strontium ranelate (bivalos)].
Dydykina IS; Tsurko VV
Ter Arkh; 2008; 80(5):85-91. PubMed ID: 18590124
[No Abstract] [Full Text] [Related]
24. Cost-effectiveness strategies to treat osteoporosis in elderly women.
Pfister AK; Welch CA; Lester MD; Emmett MK; Saville PD; Duerring SA
South Med J; 2006 Feb; 99(2):123-31. PubMed ID: 16509549
[TBL] [Abstract][Full Text] [Related]
25. Treatment of osteoporosis with parathyroid hormone and teriparatide.
Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K
Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037
[TBL] [Abstract][Full Text] [Related]
26. [Osteoporosis - Evidence based therapy].
Minne HW; Begerow B; Pfeifer M
Z Gastroenterol; 2002 Apr; 40 Suppl 1():S57-S61. PubMed ID: 11930292
[TBL] [Abstract][Full Text] [Related]
27. A comparison between bisphosphonates and other treatments for osteoporosis.
Le Goff B; Guillot P; Glémarec J; Berthelot JM; Maugars Y
Curr Pharm Des; 2010; 16(27):3037-44. PubMed ID: 20722614
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
[TBL] [Abstract][Full Text] [Related]
29. Is treatment of early postmenopausal women with bisphosphonates justified?
Epstein S
Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
[TBL] [Abstract][Full Text] [Related]
30. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
31. New developments in the treatment of osteoporosis.
Eriksen EF; Halse J; Moen MH
Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
[TBL] [Abstract][Full Text] [Related]
32. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.
Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ
Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511
[TBL] [Abstract][Full Text] [Related]
33. Clinical practice. Postmenopausal osteoporosis.
Rosen CJ
N Engl J Med; 2005 Aug; 353(6):595-603. PubMed ID: 16093468
[No Abstract] [Full Text] [Related]
34. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
[TBL] [Abstract][Full Text] [Related]
35. [How to take charge of osteoporosis in women in 2005].
Rev Infirm; 2005 Nov; (115):10-4. PubMed ID: 16375239
[No Abstract] [Full Text] [Related]
36. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
37. [Prevention of hip fractures in the elderly: where are we in 2003?].
Reginster JY; Lecart MP; Sarlet N; Halkin V
Rev Med Liege; 2003 Apr; 58(4):183-90. PubMed ID: 12875249
[TBL] [Abstract][Full Text] [Related]
38. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
Boonen S
Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
[TBL] [Abstract][Full Text] [Related]
39. Strontium ranelate in the prevention of osteoporotic fractures.
Reginster JY; Malaise O; Neuprez A; Bruyere O
Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720
[TBL] [Abstract][Full Text] [Related]
40. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.
Borgström F; Ström O; Marin F; Kutahov A; Ljunggren O
J Med Econ; 2010; 13(3):381-92. PubMed ID: 20604678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
